Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100S94E
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥734.8bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥1.39T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥681.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥6.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥5.8bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥7.9bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥19.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥13.0bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥801.4bnat 2023-09-30Cons.Assets
Total assets¥715.3bnat 2023-03-31Cons.Assets
Total assets¥740.6bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥556.2bnat 2023-09-30Cons.Liabilities
Total liabilities¥472.4bnat 2023-03-31Cons.Liabilities
Net assets / equity¥245.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥137.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥86.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥133.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥81.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥53.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥9m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥3.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥4.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥13.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥134.192023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥112.262023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥196.72022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥121.192023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥180.672022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio30.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥895m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2023-04-01 → 2023-09-30¥5.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2023-04-01 → 2023-09-30¥436m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2023-04-01 → 2023-09-30¥709.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2023-04-01 → 2023-09-30¥684.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥24.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥678m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥764.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥734.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥29.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥8.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥656.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥632.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥709.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥681.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 581
ItemContextValueUnit
Bonds payablePrior1YearInstant－JPY
Bonds payableCurrentQuarterInstant22103000000JPY
Long term loans payablePrior1YearInstant6472000000JPY
Long term loans payableCurrentQuarterInstant6284000000JPY
Net defined benefit liabilityPrior1YearInstant2508000000JPY
Net defined benefit liabilityCurrentQuarterInstant2523000000JPY
Asset retirement obligations nclPrior1YearInstant2747000000JPY
Asset retirement obligations nclCurrentQuarterInstant2649000000JPY
Provision for loss on anti monopoly act nclPrior1YearInstant4849000000JPY
Provision for loss on anti monopoly act nclCurrentQuarterInstant4849000000JPY
Other nclPrior1YearInstant15605000000JPY
Other nclCurrentQuarterInstant15073000000JPY
Noncurrent liabilitiesPrior1YearInstant32183000000JPY
Noncurrent liabilitiesCurrentQuarterInstant53483000000JPY
LiabilitiesPrior1YearInstant472372000000JPY
LiabilitiesCurrentQuarterInstant556237000000JPY
Capital stockPrior1YearInstant10649000000JPY
Capital stockCurrentQuarterInstant10649000000JPY
Capital surplusPrior1YearInstant49146000000JPY
Capital surplusCurrentQuarterInstant49154000000JPY
Retained earningsPrior1YearInstant191531000000JPY
Retained earningsCurrentQuarterInstant199266000000JPY
Treasury stockPrior1YearInstant-23107000000JPY
Treasury stockCurrentQuarterInstant-29079000000JPY
Shareholders equityPrior1YearInstant228219000000JPY
Shareholders equityCurrentQuarterInstant229990000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant18734000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant19192000000JPY
Revaluation reserve for landPrior1YearInstant-4276000000JPY
Revaluation reserve for landCurrentQuarterInstant-4283000000JPY
Valuation and translation adjustmentsPrior1YearInstant14458000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant14909000000JPY
Subscription rights to sharesPrior1YearInstant146000000JPY
Subscription rights to sharesCurrentQuarterInstant144000000JPY
Non controlling interestsPrior1YearInstant92000000JPY
Non controlling interestsCurrentQuarterInstant98000000JPY
Net assetsPrior1YearInstant242916000000JPY
Net assetsCurrentQuarterInstant245142000000JPY
Liabilities and net assetsPrior1YearInstant715288000000JPY
Liabilities and net assetsCurrentQuarterInstant801379000000JPY
Net salesPrior1YTDDuration681470000000JPY
Net salesCurrentYTDDuration734846000000JPY
Cost of salesPrior1YTDDuration626812000000JPY
Cost of salesCurrentYTDDuration678210000000JPY
Gross profitPrior1YTDDuration54658000000JPY
Gross profitCurrentYTDDuration56635000000JPY
Directors compensations salaries and allowances sgaPrior1YTDDuration20136000000JPY
Directors compensations salaries and allowances sgaCurrentYTDDuration20131000000JPY
Provision for bonuses sgaPrior1YTDDuration3314000000JPY
Provision for bonuses sgaCurrentYTDDuration3296000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass